Actinobac Biomed, Inc. is a venture-backed New Jersey-based company founded in 2009 with headquarters in North Brunswick. The current focus of its activities involves the development of pharmaceutical technologies based upon the natural biologic agent leukotoxin (Leukothera™), which targets Leukocyte Function Antigen-1 (LFA-1) on white blood cells. The company has exclusive rights to the therapeutic use of Leukothera™ through a license from the University of Medicine and Dentistry of New Jersey (UMDNJ).
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/22/13 | $100,000 | Second Round |
Foundation Venture Capital Group | undisclosed |
